Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay

Bone Marrow Transplantation

Volumn 21, Issue 6, 1998, Pages 553-560

  Smit, W M ^a   Rijnbeek, M ^a   Van Bergen, C A M ^a   Willemze, R ^a   Falkenburg, J H F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chronic myeloid leukemia; Cytotoxic T lymphocytes; Host reactive; Limiting dilution assay

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

ARTICLE; CANCER RECURRENCE; CASE REPORT; CELL CLONE; CELL SPECIFICITY; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DILUTION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKOCYTE TRANSFUSION; LIMITING DILUTION ASSAY; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0031884997     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701135     Document Type: Article

References (33)

1. Antin JH. Graft-versus-leukemia: no longer an epiphenomenon. Blood 1993; 82: 2273-2277.
2. Apperley JF, Jones L, Hale G et al. Bone marrow transplantation for patients with chronic myeloid leukemia: T-cell depletion with Campath-1 reduces the incidence of graft-ver-sus-host disease but may increase the risk of leukemic relapse. Bone Marrow Transplant 1986; 1: 53-66.
3. Maraninchi D, Biaise D, Rio B et al. Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standard risk leukemias. Lancet 1987; II: 175-178.
4. Goldman JM, Gale RP, Horowitz MM el al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
5. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leuke-mia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
6. Kolb HJ, Mittermüller J, Clemm Ch el al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
7. Bär BMAM, Schattenberg A, Mensink EJBM el al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 1993; 11: 513-519.
8. Porter DL, Roth MS, McGarigle C el al. Induction of graftversus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl J Med 1994; 330: 100-106.
9. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
10. Collins RH, Shpilberg O, Drobyski WR et al Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
11. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leuko-cytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia from graft-versus-host disease. Blood 1995; 86: 1261-1268.
12. Faber LM, van Luxemburg-Heijs SAP, Willemze R, Falken-burg JHF. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical donor of a patient with leukemia. J Exp Med 1992; 176: 1283-1289.
13. Falkenburg JHF, Faber LM, van den Elshout M et al. Generation of donor-derived antileukemic cytotoxic T lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation. J Immunother 1993; 14: 305-309.
14. Faber LM, van Luxemburg-Heijs SAP, Veenhof WFJ et al. Generation of CD4+ cytotoxic T lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood 1995; 86: 2821-2828.
15. Falkenburg JHF, Willemze R, Donor cell mediated antileu-kemic reactivity after allogeneic bone marrow transplantation. Curr Opin Hematol 1993; 1: 228-233.
16. van Lochem E, de Gast B, Goulmy E, In vitro separation of host specific graft-versus-host and graft-versus-leukemia T cell activities. Bone Marrow Transplant 1992; 10: 181-183.
17. 1 cells from the same patient. Blood 1994; 83: 3390-3402.
18. van Lochern EG, Bakker A, Snijder S et nl. Epstein-Barr virus infection abrogates the stimulatory capacity of B cells to a major histocompatibility complex class-II-restricted proliferative T-cell clone. Hum Immunol 1995; 42: 137-144.
19. Kaminski E, Hows J, Man S el al. Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation 1989; 48: 608-613.
20. Bouma GJ, van der Meer-Pnns PMW, van Bree FPMJ et al. Determination of cytotoxic T-lymphocyte precursor frequencies using europium labeling as a non-radioactive alternative to labeling with chromium-51. Hum Immunol 1992; 35: 85-92.
21. Goulmy E, HLA-A-B restriction of cytotoxic T cells. In: Ferrone S, Solheim BG (eds). HLA-typing: Methodology and Clinical Aspects. CRC Press: New York, 1982. p 105.
22. Sharrock CEM, Kaminski E, Man S, Limiting dilution analysis of human T cells: a useful clinical tool. Immunol Today 1990; 11: 281-286.
23. Strijbosch LWG, Buurman WA, Does RJMM et al. Limiting dilution assays: experimental design and statistical analysis. J Immunol Methods 1987; 97: 133-140.
24. Heslop HE, Brenner MK, Rooney CM, Donor T cells as therapy for EBV lymphoproliferation post bone marrow transplant. New Engl J Med 1994; 331: 679-680.
25. Rooney CM, Smith CA, Ng CYC et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
26. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against CMV in recipients of allogeneic bone marrow transplantation by adoptive transfer of T cell clones from the donor. New Engl J Med 1995; 333: 1038-1044.
27. Roosnek E, Hogendijk S, Zawadynski S et al. The frequency of pretransplant donor cytotoxic T cell precursors with antihost specificity predicts survival of patients transplanted with bone marrow from donors other than HLA-identical siblings. Transplantation 1993; 56: 691-696.
28. Schwarer AP, Jiang YZ, Deacock S et al. Comparison of helper and cytotoxic antirecipient T cell frequencies in unrelated bone marrow transplantation. Transplantation 1994; 58: 1198-1203.
29. Fussell ST, Donnellan M, Cooley MA, Farrell C, Cytotoxic T lymphocyte precursor frequency does not correlate with either the incidence or severity of graft-versus-host disease after matched unrelated bone marrow transplantation. Transplantation 1994; 57: 673-676.
30. de Bueger M, Bakker A, van Rood JJ et al. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T-lymphocyte defined non-MHC antigens. J Immunol 1992; 149: 1788-1794.
31. Hoffmann T, Theobald M, Bunjes D et al. Frequency of bone marrow T cells responding to HLA-identical non-leukemic and Ieukemic stimulator cells. Bone Marrow Transplant 1993; 12: 1-8.
32. Marijt WAF, Veenhof WFJ, Brand A et al. Minor histocom-patibility antigen-specific T cell lines, capable of lysing human hematopoietic progenitor cells, can be generated in vitro by stimulating with HLA-identical bone marrow cells. J Exp Med 1991; 173: 101-109.
33. Marijt WAF, Kernan NA, Diaz-Barrientos T el al. Multiple minor histocompatibility antigen specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation. Bone Marrow Transplant 1995; 16: 125-132.